141 related articles for article (PubMed ID: 37184947)
1. Second primary cancers and survival among neuroendocrine tumor patients.
Bateni SB; Coburn NG; Law C; Singh S; Myrehaug S; Assal A; Hallet J
Endocr Relat Cancer; 2023 Aug; 30(8):. PubMed ID: 37184947
[TBL] [Abstract][Full Text] [Related]
2. Characterization of a Novel Entity of G3 (High-grade Well-differentiated) Colorectal Neuroendocrine Tumors (NET) in the SEER Database.
Punekar SR; Kaakour D; Masri-Lavine L; Hajdu C; Newman E; Becker DJ
Am J Clin Oncol; 2020 Dec; 43(12):846-849. PubMed ID: 32910023
[TBL] [Abstract][Full Text] [Related]
3. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States.
Dasari A; Shen C; Halperin D; Zhao B; Zhou S; Xu Y; Shih T; Yao JC
JAMA Oncol; 2017 Oct; 3(10):1335-1342. PubMed ID: 28448665
[TBL] [Abstract][Full Text] [Related]
4. The risk and prognostic factors for G1 pancreatic neuroendocrine tumors: A retrospective analysis of the SEER database.
Wu Z; Qiu X; Zhi Y; Shi X; Lv G
Front Oncol; 2022; 12():993524. PubMed ID: 36276109
[TBL] [Abstract][Full Text] [Related]
5. Association of First Primary Cancer With Risk of Subsequent Primary Cancer Among Survivors of Adult-Onset Cancers in the United States.
Sung H; Hyun N; Leach CR; Yabroff KR; Jemal A
JAMA; 2020 Dec; 324(24):2521-2535. PubMed ID: 33351041
[TBL] [Abstract][Full Text] [Related]
6. Endoscopic and surgical treatment of T1N0M0 colorectal neuroendocrine tumors: a population-based comparative study.
Zhu H; Zhao S; Zhang C; Ji K; Wu W; Yin L; Yan H; Zhou J; Tang R; Miao L
Surg Endosc; 2022 Apr; 36(4):2488-2498. PubMed ID: 33987767
[TBL] [Abstract][Full Text] [Related]
7. Primary neuroendocrine tumors of the ovary: Management and outcomes.
Pang L; Guo Z
Cancer Med; 2021 Dec; 10(23):8558-8569. PubMed ID: 34773393
[TBL] [Abstract][Full Text] [Related]
8. Racial disparities in pancreatic neuroendocrine tumors survival: a SEER study.
Zhou H; Zhang Y; Wei X; Yang K; Tan W; Qiu Z; Li S; Chen Q; Song Y; Gao S
Cancer Med; 2017 Nov; 6(11):2745-2756. PubMed ID: 28980417
[TBL] [Abstract][Full Text] [Related]
9. Metastasis Prevalence and Survival of Patients with T1-2 Gastric Neuroendocrine Tumor Treated with Endoscopic Therapy and Surgery.
Wang M; Cheng S; Zhu L; Xu T; Zhang J; Zhang Y; Ping J; Wang R
Dig Dis Sci; 2022 Jul; 67(7):3228-3238. PubMed ID: 34272627
[TBL] [Abstract][Full Text] [Related]
10. The efficacy of chemotherapy and operation in patients with colorectal neuroendocrine carcinoma.
Wu Z; Yu D; Zhao S; Gao P; Song Y; Sun Y; Chen X; Wang Z
J Surg Res; 2018 May; 225():54-67. PubMed ID: 29605035
[TBL] [Abstract][Full Text] [Related]
11. Revisiting a dogma: similar survival of patients with small bowel and gastric GIST. A population-based propensity score SEER analysis.
Guller U; Tarantino I; Cerny T; Ulrich A; Schmied BM; Warschkow R
Gastric Cancer; 2017 Jan; 20(1):49-60. PubMed ID: 26649434
[TBL] [Abstract][Full Text] [Related]
12. Prognostic nomogram based on the metastatic lymph node ratio for gastric neuroendocrine tumour: SEER database analysis.
Li J; Lin Y; Wang Y; Lin H; Lin F; Zhuang Q; Lin X; Wu J
ESMO Open; 2020 Apr; 5(2):. PubMed ID: 32253246
[TBL] [Abstract][Full Text] [Related]
13. Second cancers in patients with neuroendocrine tumors.
Tsai HJ; Wu CC; Tsai CR; Lin SF; Chen LT; Chang JS
PLoS One; 2013; 8(12):e86414. PubMed ID: 24392036
[TBL] [Abstract][Full Text] [Related]
14. Outcomes for Surgery in Stage IA Large Cell Lung Neuroendocrine Compared With Other Types of Non-Small Cell Lung Cancer: A Propensity Score Matching Study Based on the Surveillance, Epidemiology, and End Results (SEER) Database.
Zou L; Guo T; Ye L; Zhou Y; Chu L; Chu X; Ni J; Zhu Z; Yang X
Front Oncol; 2020; 10():572462. PubMed ID: 33324549
[TBL] [Abstract][Full Text] [Related]
15. Trends in Risks for Second Primary Cancers Associated With Index Human Papillomavirus-Associated Cancers.
Suk R; Mahale P; Sonawane K; Sikora AG; Chhatwal J; Schmeler KM; Sigel K; Cantor SB; Chiao EY; Deshmukh AA
JAMA Netw Open; 2018 Sep; 1(5):e181999. PubMed ID: 30646145
[TBL] [Abstract][Full Text] [Related]
16. Increased incidence of a second lymphoproliferative malignancy in patients with multiple myeloma--a SEER based study.
Chakraborty S; Hauke RJ; Bonthu N; Tarantolo SR
Anticancer Res; 2012 Oct; 32(10):4507-15. PubMed ID: 23060579
[TBL] [Abstract][Full Text] [Related]
17. Resection of Primary Gastrointestinal Neuroendocrine Tumor Among Patients with Non-Resected Metastases Is Associated with Improved Survival: A SEER-Medicare Analysis.
Tsilimigras DI; Hyer JM; Paredes AZ; Ejaz A; Cloyd JM; Beane JD; Dillhoff M; Tsung A; Pawlik TM
J Gastrointest Surg; 2021 Sep; 25(9):2368-2376. PubMed ID: 33403563
[TBL] [Abstract][Full Text] [Related]
18. Clinical and sociodemographic risk factors associated with the development of second primary cancers among postmenopausal breast cancer survivors.
Bailey S; Ezratty C; Mhango G; Lin JJ
Breast Cancer; 2023 Mar; 30(2):215-225. PubMed ID: 36316601
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological features and prognosis factors for survival in elderly patients with pancreatic neuroendocrine tumor: A STROBE-compliant article.
Li G; Tian ML; Bing YT; Tao LY; Wang HY; Jiang B; Yuan CH; Xiu DR
Medicine (Baltimore); 2019 Mar; 98(11):e14576. PubMed ID: 30882623
[TBL] [Abstract][Full Text] [Related]
20. Comparable survival benefit of local excision versus radical resection for 10- to 20-mm rectal neuroendocrine tumors.
Chen Q; Chen J; Huang Z; Zhao H; Cai J
Eur J Surg Oncol; 2022 Apr; 48(4):864-872. PubMed ID: 34753616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
